- Home
- ABLV vs UNCY Comparison
ABLV vs UNCY Comparison
Compare ABLV & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- UNCY
- Stock Information
- Founded
- ABLV 2015
- UNCY 2016
- Country
- ABLV China
- UNCY United States
- Employees
- ABLV N/A
- UNCY N/A
- Industry
- ABLV
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- UNCY Health Care
- Exchange
- ABLV Nasdaq
- UNCY Nasdaq
- Market Cap
- ABLV 51.4M
- UNCY 56.4M
- IPO Year
- ABLV N/A
- UNCY 2021
- Fundamental
- Price
- ABLV $0.97
- UNCY $4.07
- Analyst Decision
- ABLV
- UNCY Strong Buy
- Analyst Count
- ABLV 0
- UNCY 4
- Target Price
- ABLV N/A
- UNCY $63.75
- AVG Volume (30 Days)
- ABLV 7.5K
- UNCY 482.9K
- Earning Date
- ABLV 04-23-2025
- UNCY 08-14-2025
- Dividend Yield
- ABLV N/A
- UNCY N/A
- EPS Growth
- ABLV N/A
- UNCY N/A
- EPS
- ABLV N/A
- UNCY N/A
- Revenue
- ABLV $128,932,647.00
- UNCY N/A
- Revenue This Year
- ABLV N/A
- UNCY N/A
- Revenue Next Year
- ABLV N/A
- UNCY $1,178.98
- P/E Ratio
- ABLV N/A
- UNCY N/A
- Revenue Growth
- ABLV N/A
- UNCY N/A
- 52 Week Low
- ABLV $0.55
- UNCY $2.83
- 52 Week High
- ABLV $1.90
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- ABLV 49.47
- UNCY 40.33
- Support Level
- ABLV $0.77
- UNCY $3.86
- Resistance Level
- ABLV $1.00
- UNCY $4.97
- Average True Range (ATR)
- ABLV 0.06
- UNCY 0.30
- MACD
- ABLV -0.00
- UNCY 0.04
- Stochastic Oscillator
- ABLV 68.64
- UNCY 18.92
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.